Compare Twist Bioscience Corp (TWST) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard Growth Index Fund ETF — how do they compare? Twist Bioscience Corp trades at $157.95 (market cap $10.32B), while Vanguard Growth Index Fund ETF trades at $91.99 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 37.3× Twist Bioscience Corp's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| TWST | VUG | |
|---|---|---|
Market Cap | $10.32B | $384.60B |
Volume | 5,894,998 | 4,760,473 |
Sector | Health | Sector/Thematic |
52-Week High | $205.00 | $92.64 |
52-Week Low | $25.45 | $70.00 |
Typical Hold Time | 27 Days | 47 Days |
Enterprise Value | $10.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
VUG trades at $92.42, down 0.24% with bullish technical signals from moving averages but bearish oscillators suggesting potential overbought conditions. The ETF maintains strong long-term performance with 12% average annual returns since inception, though current RSI levels indicate near-term caution. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings.
Long-term growth prospects remain favorable given VUG's historical outperformance and low 0.03% expense ratio. However, significant concentration risk in technology sector and elevated RSI levels present near-term headwinds. The ETF's value proposition centers on cost-efficient exposure to large-cap growth stocks for investors with multi-decade time horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
